Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Study supports Innogenetics' tests for AD (Alzheimer's disease)

This article was originally published in Clinica

Executive Summary

The combination of two cerebrospinal fluid (CSF)-based tests for Alzheimer's disease (AD) can confirm or rule out the disease with an accuracy of more than 90%, according to a Swedish study. The researchers say that the tests, which detect levels of beta-amyloid-42 peptide and tau protein respectively, should be included in the clinical work-up of patients with cognitive impairment, especially to differentiate early AD from normal ageing and psychiatric disorders.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT070752

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel